Nasal and Plasma SARS-CoV-2 RNA Levels are Associated with Timing of Symptom Resolution in the ACTIV-2 Trial of Non-hospitalized Adults with COVID-19

Authors :: Yijia, Li
Linda J, Harrison
Kara W, Chew
Judy S, Currier
David A, Wohl
Eric S, Daar
Teresa H, Evering
Ryan, Wu
Mark, Giganti
Justin, Ritz
Arzhang Cyrus, Javan
Robert, Coombs
Carlee, Moser
Michael D, Hughes
Joseph J, Eron
Davey M, Smith
Jonathan Z, Li
Source :: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
Publication Year :: 2022
Abstract: Acute COVID-19 symptoms limit daily activities, but little is known about its association with SARS-CoV-2 viral burden. In this exploratory analysis of placebo recipients in the ACTIV-2/A5401 platform trial, we showed that high anterior nasal (AN) RNA levels and detectable plasma RNA were associated with delayed symptom improvement.

ISSN :: 15376591
Database :: OpenAIRE
Journal :: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Accession number :: edsair.pmid..........cf89e79c83354631bfa144409c8da789

Tools